Table 3.

Univariate and Multivariate Analysis of Risk Factors and Impact on Overall Survival.

Characteristic	Univariate analysis				Multivariate analysis
	No. of Patients	HR	95% CI	p value (Log-Rank)	No. of Patients	HR	95% CI	p value (Wald test)
Age (≤70 vs. >70)	73	0.6	0.34–1.06	0.08	54	0.63	0.24–1.63	0.63
Sex (M vs. F)	73	1.29	0.77–2.19	0.33	54	0.79	0.37–1.66	0.53
BMI (≤25 vs. >25)	72	1.13	0.67–1.91	0.63	54	0.78	0.35–1.73	0.53
Tumor stage (III vs. IV)	73	0.71	0.38–1.36	0.31	54	0.73	0.26–2.06	0.56
Teatment (FFRNX vs. G/N)	73	0.55	0.32–0.95	0.03	54	0.65	0.18–3.2	0.36
Liver metastases Stage IV (Yes vs. No)	60	1.52	0.74–3.16	0.26		–	–	–
Elevated CA 19-9 (>100) at study the entry (Yes vs. No)	73	0.84	0.45–1.56	0.58		–	–	–
Elevated CA 19-9 (>1000) at study the entry (Yes vs. No)	73	1.57	0.92–2.67	0.09	54	1.18	0.48–2.9	0.7
50% Drop in CA 19-9 at any point (Yes vs. No)	42	0.26	0.09–0.67	0.005		–	–	–
50% Drop in CA 19-9 @3 months after Dx (Yes vs. No)	37	0.67	0.32–1.45	0.31		–	–	–
Diabetes at the study entry (Yes vs. No)	73	1.42	0.83–2.46	0.2		–	–	–
Diabetes type
(No vs. LS)	57	0.75	0.38–1.47	0.4	54	1.08	0.42–2.79	0.42
(NOD vs. LS)	31	0.78	0.35–1.73	0.55	54	1.24	0.44–3.51	0.67
(NOD vs. No)	57	1.04	0.55–1.99	0.89	54	1.14	0.48–2.7	0.75
RBG-pre avg. 3 months prior to Dx (≤140 vs. >140)	73	0.54	0.29–0.97	0.03	54	0.68	0.29–1.64	0.39
RBG avg. 3 months after Dx (≤120 vs. >120)	54	0.38	0.19–0.75	0.005	54	0.39	0.16–0.98	0.04
Metformin (Yes vs No)	32	1.02	0.47–2.22	0.94		–	–	-
Insulin (Yes vs No)	32	0.98	0.44–2.19	0.96		–	–	-
Other steroid use (Yes vs No)	73	0.9	0.50–1.61	0.72		–	–	-
10% drop in weight within 3 months of Dx (Yes vs. No)	54	1.36	0.71–2.64	0.35		–	–	-

Bold value represent statistical significance (p < 0.05).